Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 4/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | F3 | P13726 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.37 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10179592 | 1.00 | AHR (0.50) | AHRNR4A2CYP2A6CSNK2A1HDAC6 | |
| SCHEMBL29563719 | 0.83 | AHR (0.50) | AHRNR4A2CYP2A6CSNK2A1GPR84 | |
| SCHEMBL1513255 | 0.83 | AHR (0.50) | AHRNR4A2CYP2A6CSNK2A1GPR84 | |
| Ethoxycarbonyl Group SCHEMBL27658731 | 0.81 | CYP2A6 (0.36) | AHRNR4A2CYP2A6CSNK2A1HDAC6 | |
| SCHEMBL12680497 | 0.76 | NPC1 (0.56) | AHRNR4A2CYP2A6NPC1DYRK1B | |
| SCHEMBL8664673 | 0.75 | PDPK1 (0.47) | AHRNR4A2CYP2A6CSNK2A1HDAC6 | |
| SCHEMBL14041127 | 0.75 | GPR84 (0.52) | AHRNR4A2CYP2A6CSNK2A1HDAC6 | |
| SCHEMBL8296659 | 0.75 | CYP2A6 (0.47) | AHRNR4A2CYP2A6CSNK2A1HDAC6 | |
| SCHEMBL21090062 | 0.75 | HDAC6 (0.43) | AHRNR4A2CYP2A6CSNK2A1HDAC6 | |
| SCHEMBL30758727 | 0.75 | CYP2A6 (0.47) | AHRNR4A2CYP2A6CSNK2A1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720037-A1 | CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | 16380026 Canada Inc. (CA) | 2026-04-08 | — | — | EP | disclosed |
| US-20250179066-A1 | ZWITTERIONIC ANTIBACTERIAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-06-05 | — | — | US | disclosed |
| CN-115611925-B | HPK1 inhibitors and uses thereof | 轩竹生物科技股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-115768761-B | Novel benzimidazole derivatives | 卡尔那生物科学株式会社 | 2025-02-25 | — | — | CN | disclosed |
| WO-2024130095-A9 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-08-02 | — | — | WO | disclosed |
| CN-118255685-A | Tricyclic compound, pharmaceutical composition and application thereof | 珂阑(上海)医药科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-110637011-B | Fanisole X receptor agonist and application thereof | 奥加诺沃公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2024081653-A2 | METHODS OF LOWERING MIRO2 TO TREAT NEURODEGENERATIVE DISEASES | ACUREX BIOSCIENCES CORPORATION (US) | 2024-04-18 | — | — | WO | disclosed |
| CN-117751117-A | SARM1 enzyme activity inhibitor and application thereof | 科辉智药生物科技（无锡）有限公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-4313944-A1 | METAP-2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF | Canwell Biotech Limited (HK) | 2024-02-07 | — | — | EP | disclosed |
| EP-4301759-A2 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | The Board of Trustees of the Leland Stanford Junior University (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-111406054-B | 1,2, 4-oxadiazole derivatives as inhibitors of histone deacetylase 6 | 奥莱松基因组股份有限公司 | 2024-01-02 | — | — | CN | disclosed |
| US-20230382926-A1 | COMPOUNDS AND USES THEREOF | THE UNIVERSITY OF THE WEST INDIES (TT) | 2023-11-30 | — | — | US | disclosed |
| CN-115768761-A | Novel benzimidazole derivatives | 卡尔那生物科学株式会社 | 2023-03-07 | — | — | CN | disclosed |
| CN-111278823-B | Heterocyclic compounds as fibroblast growth factor receptor inhibitors | 上海新契博生物科技有限公司 | 2023-01-24 | — | — | CN | disclosed |
| CN-115611925-A | HPK1 inhibitors and uses thereof | 轩竹生物科技股份有限公司 | 2023-01-17 | — | — | CN | disclosed |
| WO-2022216386-A9 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022216386-A2 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022206350-A1 | METAP-2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF | CANWELL BIOTECH LIMITED (CN) | 2022-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382926-A1 | COMPOUNDS AND USES THEREOF | CFTR, CCL11, CEL | AHR 1989/4885NR4A2 4544/4885CYP2A6 1063/4885 |
| US-20250179066-A1 | ZWITTERIONIC ANTIBACTERIAL COMPOUNDS | MRPL21, WIZ, CFTR | AHR 3310/4885NR4A2 3876/4885CYP2A6 2634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.